PT - JOURNAL ARTICLE AU - Omae, Kenji AU - Onishi, Akira AU - Sahker, Ethan AU - Furukawa, Toshi A TI - Accelerated approval of non-cancer drugs by the US Food and Drug Administration: A protocol for a meta-epidemiological investigation AID - 10.1101/2020.05.18.20105148 DP - 2020 Jan 01 TA - medRxiv PG - 2020.05.18.20105148 4099 - http://medrxiv.org/content/early/2020/05/22/2020.05.18.20105148.short 4100 - http://medrxiv.org/content/early/2020/05/22/2020.05.18.20105148.full AB - The US Food and Drug Administration (FDA) ’s accelerated approval program, in which drugs are approved on the basis of surrogate endpoints, has been a source of controversy in the context of risk-benefit trade-offs. The FDA recently reported on the 25-year experience with the program and concluded that the low failure rate in post-approval confirmatory trials was evidence that the program was operating effectively. However, many studies have revealed manufacturers’ poor adherence to obligation of conducting confirmatory trials, and also concerned the harm and cost of cancer drugs approved through this program based on the limited evidence. To date, few studies have investigated accelerated approval of non-cancer drugs. Therefore, the purpose of this study is to review trends in the FDA’s utilization of its accelerated approval program for non-cancer drugs and clarify the status of fulfillment of social obligations by the FDA and sponsors in the program. The FDA’s documents will be reviewed at Drugs@FDA to identify pre-approval and confirmatory trials and regulatory updates for drug indications granted accelerated approval other than cancer treatments. We will further search PubMed, Google/Google Scholar, and the sponsors’ websites to match each identified confirmatory trial to publications in the medical literature.Competing Interest StatementKO reports a speaker fee from Ono Pharmaceutical and Astellas Pharma, and a consultant fee from Kyowa Hakko Kirin, outside the submitted work. AO reports a speaker fee from Chugai, Ono Pharmaceutical, Eli Lilly, Mitsubishi-Tanabe, Asahi-Kasei, and Takeda, and research grant from Advantest, outside the submitted work. TAF reports personal fees from Mitsubishi-Tanabe, MSD and Shionogi, and a grant from Mitsubishi-Tanabe, outside the submitted work; TAF has a patent 2018-177688 pending. ES declares that there is no competing interest.Clinical TrialUMIN000039281Funding StatementThis study does not receive any specific grant from funding agencies in the public, commercial or not-for-profit.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data generated during the current study will be available from the corresponding author on reasonable request.